Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
- Conditions
- Coronary Artery Disease
- Interventions
- Other: No antiplatelet or anticoagulant group
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-11
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 9930
- Registration Number
- NCT05845489
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Other, Korea, Republic of
Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy
- Conditions
- Coronary Artery DiseasePlatelet Reactivity
- Interventions
- Drug: CYP2C19 genotype guided P2Y12 monotherapy
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- St. Antonius Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT05773989
- Locations
- 🇳🇱
St. Antonius Hospital, Nieuwegein, Utrecht, Netherlands
Coronary Artery Ectasia, Efficacy of Various Anti Thrombotic Regimens.
- Conditions
- Coronary Artery Ectasia
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 200
- Registration Number
- NCT05718531
Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
- Conditions
- Ischemic StrokeIntracranial AtherosclerosisStenosis
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-12-21
- Target Recruit Count
- 1180
- Registration Number
- NCT05700266
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- St. Antonius Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05657041
- Locations
- 🇳🇱
StAntoniusH, Nieuwegein, Utrecht, Netherlands
🇳🇱St. Antonius Hospital, Nieuwegein, Netherlands
Drug-drug Interactions Between DWP14012 and DWC202202 in Healthy Subjects
- Conditions
- Drug Drug Interaction
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 36
- Registration Number
- NCT05574374
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- Sarmad Zahoor
- Target Recruit Count
- 90
- Registration Number
- NCT05573958
Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)
- Conditions
- Clopidogrel, Poor Metabolism ofCarotid Stenosis
- Interventions
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- IRCCS Policlinico S. Donato
- Target Recruit Count
- 1140
- Registration Number
- NCT05566301
- Locations
- 🇮🇹
IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy
Ticagrelor Versus Clopidogrel in Ischemic Stroke
- Conditions
- Ischemic Stroke
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 900
- Registration Number
- NCT05553613
- Locations
- 🇪🇬
Kafr Elsheikh University Hospital, Kafr Ash Shaykh, Egypt
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
- Conditions
- Patent Foramen OvaleMigraine
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05546320
- Locations
- 🇨🇳
Fuwai Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.